Destiny Wealth Partners’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-270
Closed -$22K – 272
2026
Q1
$22K Buy
+270
New +$22.4K ﹤0.01% 643
2023
Q1
– Sell
-270
Closed -$15.6K – 229
2022
Q4
$15.6K Hold
270
– – ﹤0.01% 432
2022
Q3
$13K Hold
270
– – ﹤0.01% 398
2022
Q2
$13K Hold
270
– – ﹤0.01% 400
2022
Q1
$17K Hold
270
– – ﹤0.01% 395
2021
Q4
$22K Hold
270
– – ﹤0.01% 382
2021
Q3
$26K Buy
+270
New +$27.3K 0.01% 354
2021
Q2
– Sell
-270
Closed -$23K – 214
2021
Q1
$23K Hold
270
– – ﹤0.01% 349
2020
Q4
$23K Buy
+270
New +$20.9K ﹤0.01% 348

Other funds holding BIB

Destiny Wealth Partners's BIB Position: Q2 2026 in Review

Destiny Wealth Partners sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2026, closing a stake of 270 shares — an estimated $22K sold.

Destiny Wealth Partners first reported a position in BIB in Q4 2020 and held it in 9 quarters. The position peaked at $26K in Q3 2021. 20 funds tracked by Wall St. Rank hold BIB as of Q2 2026.

  • Destiny Wealth Partners reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Destiny Wealth Partners sold 270 ProShares Ultra NASDAQ Biotechnology shares in Q2 2026, an estimated $22K.
  • Destiny Wealth Partners first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2020 and held it in 9 quarters.
  • Destiny Wealth Partners's ProShares Ultra NASDAQ Biotechnology position peaked at $26K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2026.

Based on Destiny Wealth Partners's 13F filing for Q2 2026, filed 7 Aug 2026.